Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression
Prostate cancer is the second leading cause of cancer-related deaths in men. Fatty acid synthase (FASN) is normally upregulated during human prostate cancer onset and metastatic progression and its expression positively correlates with the development of advanced metastatic disease. However, it rema...
Gespeichert in:
| Veröffentlicht in: | Cancer biology & therapy Jg. 6; H. 8; S. 1269 - 1274 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Taylor & Francis
01.08.2007
|
| Schlagworte: | |
| ISSN: | 1538-4047, 1555-8576, 1555-8576 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Prostate cancer is the second leading cause of cancer-related deaths in men. Fatty acid synthase (FASN) is normally upregulated during human prostate cancer onset and metastatic progression and its expression positively correlates with the development of advanced metastatic disease. However, it remains unknown what molecular factor(s) control FASN expression. It has been hypothesized that FASN functions as a tumor promoter during prostate cancer progression in humans. Consistently, an established mouse of model of prostate cancer, termed TRAMP mice, also shows the progressive upregulation of FASN levels during prostate cancer development. Here, we examine the role of caveolin-1 (Cav-1) in regulating FASN expression during prostate cancer progression. For this purpose, we crossed Cav-1 (-/-) null mice with TRAMP mice to generate TRAMP/Cav-1 (+/+) and TRAMP/Cav-1 (-/-) mice. Then, we assessed the expression of FASN in Cav-1 (+/+) and Cav-1 (-/-) prostate tumors by immunohistochemistry and Western blot analysis. Interestingly, our results indicate that FASN fails to be upregulated in Cav-1 (-/-) tumors. Importantly, the tumors examined were the same morphological grade, but Cav-1 (-/-) tumors were dramatically smaller and did not metastasize efficiently. We conclude that Cav-1 expression is normally required for the upregulation of FASN during prostate cancer progression. These results also mechanistically explain why TRAMP/Cav-1 (-/-) mice are dramatically resistant to the development of prostate tumors and lung metastases, as they lack the expression of the FASN tumor promoter. Thus, TRAMP/Cav-1 (-/-) mice will provide a novel model system to elucidate the role of FASN in prostate tumor progression. In addition, our results provide the first molecular genetic evidence that Cav-1 functions upstream of FASN during prostate cancer progression. |
|---|---|
| AbstractList | Prostate cancer is the second leading cause of cancer-related deaths in men. Fatty acid synthase (FASN) is normally upregulated during human prostate cancer onset and metastatic progression and its expression positively correlates with the development of advanced metastatic disease. However, it remains unknown what molecular factor(s) control FASN expression. It has been hypothesized that FASN functions as a tumor promoter during prostate cancer progression in humans. Consistently, an established mouse of model of prostate cancer, termed TRAMP mice, also shows the progressive upregulation of FASN levels during prostate cancer development. Here, we examine the role of caveolin-1 (Cav-1) in regulating FASN expression during prostate cancer progression. For this purpose, we crossed Cav-1 (-/-) null mice with TRAMP mice to generate TRAMP/Cav-1 (+/+) and TRAMP/Cav-1 (-/-) mice. Then, we assessed the expression of FASN in Cav-1 (+/+) and Cav-1 (-/-) prostate tumors by immunohistochemistry and Western blot analysis. Interestingly, our results indicate that FASN fails to be upregulated in Cav-1 (-/-) tumors. Importantly, the tumors examined were the same morphological grade, but Cav-1 (-/-) tumors were dramatically smaller and did not metastasize efficiently. We conclude that Cav-1 expression is normally required for the upregulation of FASN during prostate cancer progression. These results also mechanistically explain why TRAMP/Cav-1 (-/-) mice are dramatically resistant to the development of prostate tumors and lung metastases, as they lack the expression of the FASN tumor promoter. Thus, TRAMP/Cav-1 (-/-) mice will provide a novel model system to elucidate the role of FASN in prostate tumor progression. In addition, our results provide the first molecular genetic evidence that Cav-1 functions upstream of FASN during prostate cancer progression. Prostate cancer is the second leading cause of cancer-related deaths in men. Fatty acid synthase (FASN) is normally upregulated during human prostate cancer onset and metastatic progression and its expression positively correlates with the development of advanced metastatic disease. However, it remains unknown what molecular factor(s) control FASN expression. It has been hypothesized that FASN functions as a tumor promoter during prostate cancer progression in humans. Consistently, an established mouse of model of prostate cancer, termed TRAMP mice, also shows the progressive upregulation of FASN levels during prostate cancer development. Here, we examine the role of caveolin-1 (Cav-1) in regulating FASN expression during prostate cancer progression. For this purpose, we crossed Cav-1-/- null mice with TRAMP mice to generate TRAMP/Cav-1+/+ and TRAMP/Cav-1-/- mice. Then, we assessed the expression of FASN in Cav-1+/+ and Cav-1-/- prostate tumors by immuno-histochemistry and Western blot analysis. Interestingly, our results indicate that FASN fails to be upregulated in Cav-1-/- tumors. Importantly, the tumors examined were the same morphological grade, but Cav-1-/- tumors were dramatically smaller and did not metastasize efficiently. We conclude that Cav-1 expression is normally required for the upregulation of FASN during prostate cancer progression. These results also mechanistically explain why TRAMP/Cav-1-/- mice are dramatically resistant to the development of prostate tumors and lung metastases, as they lack the expression of the FASN tumor promoter. Thus, TRAMP/Cav-1-/- mice will provide a novel model system to elucidate the role of FASN in prostate tumor progression. In addition, our results provide the first molecular genetic evidence that Cav-1 functions upstream of FASN during prostate cancer progression.Prostate cancer is the second leading cause of cancer-related deaths in men. Fatty acid synthase (FASN) is normally upregulated during human prostate cancer onset and metastatic progression and its expression positively correlates with the development of advanced metastatic disease. However, it remains unknown what molecular factor(s) control FASN expression. It has been hypothesized that FASN functions as a tumor promoter during prostate cancer progression in humans. Consistently, an established mouse of model of prostate cancer, termed TRAMP mice, also shows the progressive upregulation of FASN levels during prostate cancer development. Here, we examine the role of caveolin-1 (Cav-1) in regulating FASN expression during prostate cancer progression. For this purpose, we crossed Cav-1-/- null mice with TRAMP mice to generate TRAMP/Cav-1+/+ and TRAMP/Cav-1-/- mice. Then, we assessed the expression of FASN in Cav-1+/+ and Cav-1-/- prostate tumors by immuno-histochemistry and Western blot analysis. Interestingly, our results indicate that FASN fails to be upregulated in Cav-1-/- tumors. Importantly, the tumors examined were the same morphological grade, but Cav-1-/- tumors were dramatically smaller and did not metastasize efficiently. We conclude that Cav-1 expression is normally required for the upregulation of FASN during prostate cancer progression. These results also mechanistically explain why TRAMP/Cav-1-/- mice are dramatically resistant to the development of prostate tumors and lung metastases, as they lack the expression of the FASN tumor promoter. Thus, TRAMP/Cav-1-/- mice will provide a novel model system to elucidate the role of FASN in prostate tumor progression. In addition, our results provide the first molecular genetic evidence that Cav-1 functions upstream of FASN during prostate cancer progression. Prostate cancer is the second leading cause of cancer-related deaths in men. Fatty acid synthase (FASN) is normally upregulated during human prostate cancer onset and metastatic progression and its expression positively correlates with the development of advanced metastatic disease. However, it remains unknown what molecular factor(s) control FASN expression. It has been hypothesized that FASN functions as a tumor promoter during prostate cancer progression in humans. Consistently, an established mouse of model of prostate cancer, termed TRAMP mice, also shows the progressive upregulation of FASN levels during prostate cancer development. Here, we examine the role of caveolin-1 (Cav-1) in regulating FASN expression during prostate cancer progression. For this purpose, we crossed Cav-1-/- null mice with TRAMP mice to generate TRAMP/Cav-1+/+ and TRAMP/Cav-1-/- mice. Then, we assessed the expression of FASN in Cav-1+/+ and Cav-1-/- prostate tumors by immuno-histochemistry and Western blot analysis. Interestingly, our results indicate that FASN fails to be upregulated in Cav-1-/- tumors. Importantly, the tumors examined were the same morphological grade, but Cav-1-/- tumors were dramatically smaller and did not metastasize efficiently. We conclude that Cav-1 expression is normally required for the upregulation of FASN during prostate cancer progression. These results also mechanistically explain why TRAMP/Cav-1-/- mice are dramatically resistant to the development of prostate tumors and lung metastases, as they lack the expression of the FASN tumor promoter. Thus, TRAMP/Cav-1-/- mice will provide a novel model system to elucidate the role of FASN in prostate tumor progression. In addition, our results provide the first molecular genetic evidence that Cav-1 functions upstream of FASN during prostate cancer progression. |
| Author | Hassan, Ghada S. Capozza, Franco Di Vizio, Dolores Sotgia, Federica Pestell, Richard G. Williams, Terence M. Frank, Philippe G. Loda, Massimo Freeman, Michael R. Lisanti, Michael P. |
| Author_xml | – sequence: 1 givenname: Dolores surname: Di Vizio fullname: Di Vizio, Dolores – sequence: 2 givenname: Federica surname: Sotgia fullname: Sotgia, Federica – sequence: 3 givenname: Terence M. surname: Williams fullname: Williams, Terence M. – sequence: 4 givenname: Ghada S. surname: Hassan fullname: Hassan, Ghada S. – sequence: 5 givenname: Franco surname: Capozza fullname: Capozza, Franco – sequence: 6 givenname: Philippe G. surname: Frank fullname: Frank, Philippe G. – sequence: 7 givenname: Richard G. surname: Pestell fullname: Pestell, Richard G. – sequence: 8 givenname: Massimo surname: Loda fullname: Loda, Massimo – sequence: 9 givenname: Michael R. surname: Freeman fullname: Freeman, Michael R. – sequence: 10 givenname: Michael P. surname: Lisanti fullname: Lisanti, Michael P. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/17786030$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkc1v1DAQxS1URD_gxhn5hEDaLHZsx9ljtaKAVMEBOFsTe7I1SuKt7YD2xL-O0217QD3Zsn7vjee9c3IyhQkJec3ZWvKGf7BdXjfrdi2l1M_IGVdKVa3SzclyF20lmdSn5DylX4zVum42L8gp17ptmGBn5O8WfmMY_FRx6hONeDv7iI72IdJ8g3TeR9zNA2QfJhp62kPOBwrWO5oOU76BhPTd1eX3r-9XFGiex6LbxzCGjHFF3Rz9tFseUoaM1MJk8Q7YRUypeL4kz3sYEr66Py_Iz6uPP7afq-tvn75sL68rW5bMlbU1iBpQamcZWAEdONlw3jjNWS11p1ole9VvxEZIZQF13desBcsZKsa5uCBvj75l9u2MKZvRJ4vDABOGOZlmU-JohSrgm3tw7kZ0Zh_9CPFgHiIrQH0EbNkqReyN9fkunxzBD4Yzs_RiSi-mMa1Zeimi1X-iR9-ncXbEy_ccps6HZD2W7B5lCw4xezvgg0QfJX4q3Y3wJ8TBmQyHIcQ-ltx9MuLJYf8ALdW1Qw |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0099254 crossref_primary_10_1016_j_ucl_2009_11_006 crossref_primary_10_1038_bjc_2012_246 crossref_primary_10_1002_ijc_26048 crossref_primary_10_1007_s10555_020_09874_x crossref_primary_10_1038_s41598_017_18701_3 crossref_primary_10_1016_j_mpdhp_2008_03_001 crossref_primary_10_1002_prca_200800102 crossref_primary_10_1038_pcan_2017_7 crossref_primary_10_1007_s00404_018_4841_2 crossref_primary_10_1016_j_ajpath_2012_07_030 crossref_primary_10_1007_s13277_015_3551_7 crossref_primary_10_1038_s41388_023_02668_9 crossref_primary_10_1177_030089160809400501 crossref_primary_10_1080_13813455_2024_2430488 crossref_primary_10_1016_j_ejca_2011_01_005 crossref_primary_10_1158_1541_7786_MCR_11_0451 crossref_primary_10_1016_j_bbcan_2023_189002 crossref_primary_10_1016_j_bbalip_2009_09_005 crossref_primary_10_1002_pros_21057 crossref_primary_10_1016_j_ijbiomac_2025_145410 crossref_primary_10_1111_j_1600_0854_2008_00733_x |
| ContentType | Journal Article |
| Copyright | Copyright © 2007 Landes Bioscience 2007 |
| Copyright_xml | – notice: Copyright © 2007 Landes Bioscience 2007 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.4161/cbt.6.8.4447 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1555-8576 |
| EndPage | 1274 |
| ExternalDocumentID | 17786030 10_4161_cbt_6_8_4447 10904447 |
| Genre | Research Article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01CA93596 – fundername: NCI NIH HHS grantid: R01 CA112303 – fundername: NCI NIH HHS grantid: R01CA80250 – fundername: NCI NIH HHS grantid: R01CA98779 |
| GroupedDBID | --- 00X 0VX 0YH 29B 30N 53G 5GY 6J9 AAFWJ ABCCY ABEIZ ABFIM ACGFO ACGFS ACTIO ADBBV ADCVX AECIN AEISY AENEX AFPKN AGYJP AIJEM AIYEW ALMA_UNASSIGNED_HOLDINGS ALQZU AQRUH AQTUD AVBZW BABNJ BAWUL BLEHA C1A CCCUG DGEBU DIK DKSSO E3Z EBS F5P H13 IH2 KSSTO KYCEM M4Z O9- OK1 P2P P6G RPM SJN TDBHL TFL TFW TR2 TTHFI - 0R AAAVI ABJVF ACENM AEGYZ AGCAB AIRBT AIRXU AWQZV RNANH ROSJB RTWRZ TFT TQWBC 4.4 AAYXX ACKZS ADFZZ AOIJS AURDB BFWEY CITATION CWRZV EJD EMOBN GROUPED_DOAJ HYE IPNFZ LJTGL PCLFJ RIG UDS AEXWM CGR CUY CVF ECM EIF NPM 7X8 |
| ID | FETCH-LOGICAL-c416t-cc2a32ae47dc0ac3abad46116d710247b5854f5f939345cae72f208ac10e50113 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 30 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000252666800030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1538-4047 1555-8576 |
| IngestDate | Sun Nov 09 11:27:38 EST 2025 Thu Jan 02 23:01:40 EST 2025 Sat Nov 29 05:34:10 EST 2025 Tue Nov 18 22:02:49 EST 2025 Fri Jan 15 03:37:28 EST 2021 Mon Oct 20 23:38:06 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c416t-cc2a32ae47dc0ac3abad46116d710247b5854f5f939345cae72f208ac10e50113 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.tandfonline.com/doi/pdf/10.4161/cbt.6.8.4447?needAccess=true |
| PMID | 17786030 |
| PQID | 69030835 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | crossref_citationtrail_10_4161_cbt_6_8_4447 pubmed_primary_17786030 crossref_primary_10_4161_cbt_6_8_4447 landesbioscience_primary_cbt_article_4447 informaworld_taylorfrancis_310_4161_cbt_6_8_4447 proquest_miscellaneous_69030835 |
| PublicationCentury | 2000 |
| PublicationDate | 8/1/2007 2007/08/01 2007-08-00 2007-Aug 20070801 |
| PublicationDateYYYYMMDD | 2007-08-01 |
| PublicationDate_xml | – month: 08 year: 2007 text: 8/1/2007 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer biology & therapy |
| PublicationTitleAlternate | Cancer Biol Ther |
| PublicationYear | 2007 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| SSID | ssj0027269 |
| Score | 1.9921712 |
| Snippet | Prostate cancer is the second leading cause of cancer-related deaths in men. Fatty acid synthase (FASN) is normally upregulated during human prostate cancer... |
| SourceID | proquest pubmed crossref landesbioscience informaworld |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1269 |
| SubjectTerms | Animals Binding Biology Bioscience Calcium Cancer Caveolin 1 - genetics Caveolin 1 - physiology Cell Cycle Disease Progression Fatty Acid Synthases - genetics Fatty Acid Synthases - metabolism Landes Male Mice Mice, Transgenic Organogenesis Prostatic Neoplasms - enzymology Prostatic Neoplasms - genetics Prostatic Neoplasms - pathology Proteins Up-Regulation |
| Title | Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression |
| URI | https://www.tandfonline.com/doi/abs/10.4161/cbt.6.8.4447 http://www.landesbioscience.com/journals/cbt/article/4447/ https://www.ncbi.nlm.nih.gov/pubmed/17786030 https://www.proquest.com/docview/69030835 |
| Volume | 6 |
| WOSCitedRecordID | wos000252666800030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor & Francis Online Journals customDbUrl: eissn: 1555-8576 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0027269 issn: 1538-4047 databaseCode: TFW dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKhRAcKG-WR_EBJCqabRw7iXOsKlYcYIVEEXuzJn7ASjS7ynor9cRfx2NnWwr0ANdkLD9mxjO2Z-Yj5GVTuGBIoMpcAXUmGg5Z25Qm4xqAQeFM3UbUkvf1dCpns-bjFpGbXBgMq8QztEuFIuJejcoNbUQgQXf8QLd-XI3lWAiBaeTBoUfRPp58uThpFRHLLmqzyEWdIt7_aHzJFl2qVHqL7GBgIb7RDDUl7dUuaDRFk53_n8QdcntwP-lhkpe7ZMt298iND8MD-33y4whOLeL4ZIzOV7S3GChsDQ1jpsFVpOtln8DrAzvpwlEH3p9R0HNDV2ed_xZsIn09Ofw03dunQP36JLRbxog_2-_TlBOJH2IeE9UocpHgawrH7R6Qz5O3x0fvsgGjIdNhGj7TugBegBW10TloDi0YUTFWGXRdROC0LIUrXcMbLkoNtg7CkUvQLLdl2Fv4Q7LdLTr7mNDGlo5bJl0umLCsbY0oHTOtkCDrJq9G5M2GW0oPBcwRR-O7CgcZXFMV1lRVSipc0xF5dU69TIU7rqDLf2W88vGixCVUE8X_3mTvd-E47wLpBp0faF9spEYFxcXXGOjsYr1SVYOlgng5Io-SMF0ME2v6hZ9P_n1oT8nNdPmMEYrPyLbv1_Y5ua5P_XzV75Jr9UzuRlX5CUsTGWQ |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagIB4HypvlVR9AomqzxLHz8LGqWBWxXSGxiN6siR90pZJdZbOVeuKv47HTF9AD4pqMFccz4xnbn-cj5I3MnA8kUCQugzIRkkNSy9wkXAMwyJwp68BaMi4nk-rgQH6-QPWFsEpcQ7tYKCLM1ejcuBmNHo75-Htdd8NiWA2FEOV1ciP3IRbRfNPRt_O1VhbY7II_i1SUEfP-R-tL0ehSrdK7ZB2hhXhK01eVtFcnoSEYjdb_4zfuk3t9Bkp3osk8INds85Dc2u_P2B-Rn7twbJHKJ2F0tqStRaywNdR3mvpska4WbeSv9xqlc0cddN0JBT0zdHnSdIc-LNJ3o50vk81tCrRb_fDtFgH0Z9ttGq9F4oNwlYlqtLog8D0icpvH5Ovow3R3L-lpGhLtf6NLtM6AZ2BFaXQKmkMNRhSMFQazF-GVXeXC5U5yyUWuwZbePtIKNEtt7qcX_oSsNfPGPiNU2txxyyqXCiYsq2sjcsdMLSqoSpkWA7J1qi6l-xrmSKVxpPxaBsdU-TFVhaoUjumAvD2TXsTaHVfIpRc1r7qwV-IisYnif2-y-bt1nH0C5Xq372U3Ts1Ged_FAxlo7Hy1VIXEakE8H5Cn0ZrOu4ll_fzL5__etQ1ye2-6P1bjj5NPL8iduBeNgMWXZK1rV_YVuamPu9myfR085hcjLxyd |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6Vgio4UN4sr_oAElWbJYmd17EqRCDKqhJF9GZN_ICVILvKZiv1xF_HY2dbCvQA12SsOJ4Zz9gefx_A8yq1LpBgHtkUi0hUHKOmynTEFWKCqdVF41lLDorJpDw-rg7XoFzdhaGySlpD2wAU4edqcu65tuTglI6_Uk0_zsflWAhRXIGrHhPLWfJR_fl8qZV6MjvvziIWRSh5_6P1hWB0Aar0BmxSZSEd0gygkubyHNTHonrz___iFtwc8k-2FwzmNqyZ9g5sfBhO2O_Cj308MUTkEyVsumCdoUpho5nrM3O5IlvOu8Be7_TJZpZZ7PtThmqq2eK07b-6oMhe1nsfJ9u7DFm__O7azX3Jn-l2WbgUSQ_8RSamyOa8wJdQj9veg0_1m6P9t9FA0hAp9xt9pFSKPEUjCq1iVBwb1CJPklxT7iKcqstM2MxWvOIiU2gKZx1xiSqJTeYmF34f1ttZax4Cq0xmuUlKG4tEmKRptMhsohtRYllUcT6CnZW2pBoQzIlI45t0KxkaU-nGVOaylDSmI3hxJj0PyB2XyMW_Kl72fqfEBloTyf_eZPt34zj7BMkNTj_Ibq2sRjrPpeMYbM1suZB5RVhBPBvBg2BM590kUD_38tG_d20LNg5f1_Lg3eT9Y7geNqKpWvEJrPfd0jyFa-qkny66Z95ffgKjhxtB |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Caveolin-1+is+required+for+the+upregulation+of+fatty+acid+synthase+%28FASN%29%2C+a+tumor+promoter%2C+during+prostate+cancer+progression&rft.jtitle=Cancer+biology+%26+therapy&rft.au=Di+Vizio%2C+Dolores&rft.au=Sotgia%2C+Federica&rft.au=Williams%2C+Terence+M&rft.au=Hassan%2C+Ghada+S&rft.date=2007-08-01&rft.eissn=1555-8576&rft.volume=6&rft.issue=8&rft.spage=1263&rft_id=info:doi/10.4161%2Fcbt.6.8.4447&rft_id=info%3Apmid%2F17786030&rft.externalDocID=17786030 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-4047&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-4047&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-4047&client=summon |